Skip to content


Better cancer immunotherapies for patients start
with better antigen selection

At Genocea, it is our mission to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor.

In addition to our two clinical-stage oncology programs, GEN-009 and GEN-011, we are applying ATLAS to antigen discovery in multiple other disease settings.

Click to toggle:

Unique and proprietary antigen discovery platform

ATLAS™ is a unique bioassay that enables a superior, patient biology-driven approach to identify targets of protective T cell responses. ATLAS zeroes in on only those surface-presented antigens that trigger anti-tumor T cell responses. Learn more about how ATLAS works to improve immunotherapies below.

What is ATLAS?

Pushing Boundaries

How ATLAS Works

Inhibigen: suppressesanti-tumor T cell responses Stimulatory antigen: elicitsanti-tumor T cell response Autologousdendritic cell AutologousT cell Blood sample Bacterial vectors expressing each candidate Tumor biopsy NGS analysis Uniqueplasmidsforevery candidate antigen

ATLAS antigen selection: our foundation

Foundation for effective immunotherapies
  • Included: Antigens relevant to both disease and patient immune system
  • Confirms antigens that are surface-presented and drive anti-tumor T cell responses

  • Excluded: Inhibigens, uniquely identified by ATLAS
  • CD4+ and CD8+ T cells responding to Inhibigens can promote tumor growth and compete with immunotherapy anti-tumor effects
  • For any patient, any antigen type, any disease, and both CD4+ and CD8+ T cells
  • ATLAS is a highly industrialized platform
  • Global patent families protect ATLAS into 2030s

Inhibigens™ – Identified Solely Through ATLAS

ATLAS is the only technology that can identify pro-tumor inhibitory antigens, or InhibigensTM, which subvert anti-tumor immune responses in the context of cancer immunotherapy. A growing body of foundational research led by the Genocea team has revealed the responses to Inhibigens enhance tumor growth and undermine otherwise effective immunotherapies.



Explore more information on this breakthrough research below:

Posters, Presentations, Publications and Videos

All Resources
Infectious Disease
2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
ATLAS drives Genocea’s emerging immunotherapy pipeline of clinical stage programs. Learn more about our ATLAS-driven pipeline.